HannahBlake, Author at - Page 5 of 104

Daiichi Sankyo blood thinner drug reaches phase 3 goal

Daiichi Sankyo’s blood clot and stroke prevention drug, edoxaban, has met its primary efficacy endpoint in a phase

Daiichi Sankyo blood thinner drug reaches phase 3 goal

https://pharmaphorum.com/news/daiichi-sankyo-blood-thinner-drug-reaches-phase-3-goal/

Top ten tips for motivating physical activity behavior in people with diabetes

In our metabolic diseases and diabetes focus month, Mavis Dixon from Ayogo shares her top ten tips for

Top ten tips for motivating physical activity behavior in people with diabetes

https://pharmaphorum.com/views-and-analysis/top-ten-tips-for-motivating-physical-activity-behavior-in-people-with-diabetes/

Roche’s advanced breast cancer drug approved in EU

The European Commission has approved Roche’s Kadcyla for advanced HER2-positive breast cancer. The decision is based on results

Roche’s advanced breast cancer drug approved in EU

https://pharmaphorum.com/news/roche-s-advanced-breast-cancer-drug-approved-in-eu/

Three ways ACA (Obamacare) changes pharma marketing

The Affordable Care Act (Obamacare) will dramatically alter the way pharmaceutical marketers approach their business. In this article,

Three ways ACA (Obamacare) changes pharma marketing

https://pharmaphorum.com/views-and-analysis/three-ways-aca-obamacare-changes-pharma-marketing/

Positive phase 3 for AbbVie’s hepatitis C regimen

AbbVie has presented positive phase three clinical trial results for its investigational three direct-acting-antiviral (3D) regimen plus ribavirin

Positive phase 3 for AbbVie’s hepatitis C regimen

https://pharmaphorum.com/news/positive-phase-3-for-abbvie-s-hepatitis-c-regimen/

Digital health perspectives: Serkan Erkovan

Serkan Erkovan shares his thoughts on digital within pharma in our latest ‘digital health perspective’ interview with pharmaphorum’s

Digital health perspectives: Serkan Erkovan

https://pharmaphorum.com/views-and-analysis/digital-health-perspectives-serkan-erkovan/

Amgen’s melanoma drug improved OS in phase three

Amgen’s melanoma drug has been found to improve overall survival (OS) in phase three clinical trials. The drug,

Amgen’s melanoma drug improved OS in phase three

https://pharmaphorum.com/news/amgen-s-melanoma-drug-improved-os-in-phase-three/

Marketing functional competencies – who are they really for?

Cindy Monastersky questions who marketing functional competencies really benefit in our ‘marketing excellence’ themed month.

Marketing functional competencies – who are they really for?

https://pharmaphorum.com/views-and-analysis/marketing-functional-competencies-who-are-they-really-for/

GSK, Theravance respiratory drug approved for use in Europe

The European Commission has granted marketing authorization to GSK and Theravance’s drug, Relvar Ellipta, for use across the

GSK, Theravance respiratory drug approved for use in Europe

https://pharmaphorum.com/news/gsk-theravance-respiratory-drug-approved-for-use-in-europe/

Trending

About HannahBlake

Posts by HannahBlake :

Daiichi Sankyo blood thinner drug reaches phase 3 goal

Top ten tips for motivating physical activity behavior in people with diabetes

Roche’s advanced breast cancer drug approved in EU

Three ways ACA (Obamacare) changes pharma marketing

Positive phase 3 for AbbVie’s hepatitis C regimen

Digital health perspectives: Serkan Erkovan

Amgen’s melanoma drug improved OS in phase three

Marketing functional competencies – who are they really for?

GSK, Theravance respiratory drug approved for use in Europe

Search

Advanced Search

Trending

About HannahBlake

Posts by HannahBlake :